Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated:  12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated: 12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated:  12/21/2015
Royal Prince Alfred Hospital
mi
from
Sydney,
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse
Status: Enrolling
Updated: 12/21/2015
Royal Prince Alfred Hospital
mi
from
Sydney,
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
City of Hope South Pasadena
mi
from
South Pasadena, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Northwestern University
mi
from
Chicago, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated:  12/21/2015
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma
Status: Enrolling
Updated: 12/21/2015
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery
Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Phase III Randomized Trial Study Comparing the Outcome of High-Dose IMRT (86.4 GY) Alone With IMRT to 75.6 GY Plus Neoadjuvant/Adjuvant Androgen Deprivation in Patients With High Grade Intermediate Risk and Unfavorable Risk Prostate Cancer
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Phase III Randomized Trial Study Comparing the Outcome of High-Dose IMRT (86.4 GY) Alone With IMRT to 75.6 GY Plus Neoadjuvant/Adjuvant Androgen Deprivation in Patients With High Grade Intermediate Risk and Unfavorable Risk Prostate Cancer
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
A Pilot Clinical Trial of Preoperative Cetuximab With Concurrent Continuous Infusion Fluorouracil and Pelvic Radiation in Patients With Local-Regionally Advanced Rectal Cancer
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
A Pilot Clinical Trial of Preoperative Cetuximab With Concurrent Continuous Infusion Fluorouracil and Pelvic Radiation in Patients With Local-Regionally Advanced Rectal Cancer
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Status: Enrolling
Updated:  12/21/2015
University of Rochester, James P. Wilmot Cancer Center
mi
from
Rochester, NY
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Status: Enrolling
Updated: 12/21/2015
University of Rochester, James P. Wilmot Cancer Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease: A Pilot Chemoprevention Trial
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease
Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease: A Pilot Chemoprevention Trial
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study
Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study
Quadrant High Dose Rate Intraoperative Radiation Therapy (IORT) for Early-Stage Breast Cancer: A Pilot Study
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
A Pilot Study of Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
A Pilot Study of Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
Pilot Study of Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in High-Risk Breast Cancer: Feasibility
Status: Enrolling
Updated:  12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
Pilot Study of Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in High-Risk Breast Cancer: Feasibility
Status: Enrolling
Updated: 12/21/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Highlands Oncology Group
mi
from
Springdale, AR
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Highlands Oncology Group
mi
from
Springdale, AR
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Medical Consultants, P.C.
mi
from
Muncie, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Providence Portland Medical Center
mi
from
Portland, OR
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated:  12/21/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
A Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies
Status: Enrolling
Updated: 12/21/2015
Fox Chase Cancer Center Extramural Research Program
mi
from
Rockledge, PA
Click here to add this to my saved trials
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer
Pilot Study of Ex-Vivo Molecular Polyp Imaging Using 18-F Fluorodeoxyglucose (FGD) Positron Emission Tomography (PET) in the Determination of Protein and Gene Expression Signatures of Premalignant Polyps
Status: Enrolling
Updated:  12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer
Pilot Study of Ex-Vivo Molecular Polyp Imaging Using 18-F Fluorodeoxyglucose (FGD) Positron Emission Tomography (PET) in the Determination of Protein and Gene Expression Signatures of Premalignant Polyps
Status: Enrolling
Updated: 12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  12/22/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer
A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 12/22/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Status: Enrolling
Updated:  12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Prospective Randomized, Double Blind, Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Status: Enrolling
Updated: 12/22/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated:  12/22/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated: 12/22/2015
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated:  12/22/2015
Florida Cancer Specialists, Site #179
mi
from
St. Petersburg, FL
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated: 12/22/2015
Florida Cancer Specialists, Site #179
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated:  12/22/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated: 12/22/2015
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated:  12/22/2015
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated: 12/22/2015
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated:  12/22/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated: 12/22/2015
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated:  12/22/2015
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated: 12/22/2015
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated:  12/22/2015
Virginia Cancer Institute
mi
from
Richmond, VA
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing
Status: Enrolling
Updated: 12/22/2015
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials